Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?

Tseng YD, Wootton L, Nyflot M, Apisarnthanarax S, Rengan R, Bloch C, Sandison G, St James S.

Phys Med Biol. 2018 Jan 18;63(2):02NT03. doi: 10.1088/1361-6560/aaa44e.

PMID:
29346116
2.
3.

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.

Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, Aggarwal C, Cohen RB, Langer CJ, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2018 Mar;19(2):e205-e209. doi: 10.1016/j.cllc.2017.10.001. Epub 2017 Oct 12.

PMID:
29153967
4.

The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients.

McNew LK, Bowen SR, Gopan O, Nyflot MJ, Patel SA, Zeng J, Rengan R.

Adv Radiat Oncol. 2017 Feb 1;2(2):192-196. doi: 10.1016/j.adro.2017.01.008. eCollection 2017 Apr-Jun.

5.

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.

Rwigema JM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB 2nd.

Cancer. 2017 Nov 1;123(21):4244-4251. doi: 10.1002/cncr.30870. Epub 2017 Jul 5.

PMID:
28678434
6.

Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer: The Right Dose, in the Right Location, to the Right Patient, at the Right Time.

Zeng J, Rengan R.

JAMA Oncol. 2017 Oct 1;3(10):1365-1367. doi: 10.1001/jamaoncol.2017.1344. No abstract available.

PMID:
28570727
7.

Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.

Kalbasi A, Rengan R.

Transl Lung Cancer Res. 2017 Apr;6(2):169-177. doi: 10.21037/tlcr.2017.03.03. Review.

8.

Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.

Lee E, Zeng J, Miyaoka RS, Saini J, Kinahan PE, Sandison GA, Wong T, Vesselle HJ, Rengan R, Bowen SR.

Med Phys. 2017 Jul;44(7):3418-3429. doi: 10.1002/mp.12308. Epub 2017 Jun 1.

PMID:
28453861
9.

Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry.

Dhami G, Zeng J, Vesselle HJ, Kinahan PE, Miyaoka RS, Patel SA, Rengan R, Bowen SR.

Strahlenther Onkol. 2017 May;193(5):410-418. doi: 10.1007/s00066-017-1114-0. Epub 2017 Mar 2.

PMID:
28255667
10.

Oligometastatic non-small-cell lung cancer: current treatment strategies.

Richard PJ, Rengan R.

Lung Cancer (Auckl). 2016 Nov 4;7:129-140. doi: 10.2147/LCTT.S101639. eCollection 2016. Review.

11.

First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.

Remick JS, Schonewolf C, Gabriel P, Doucette A, Levin WP, Kucharczuk JC, Singhal S, Pechet TTV, Rengan R, Simone CB 2nd, Berman AT.

Clin Lung Cancer. 2017 Jul;18(4):364-371. doi: 10.1016/j.cllc.2016.12.009. Epub 2017 Jan 5.

PMID:
28162946
12.

An image-guided precision proton radiation platform for preclinical in vivo research.

Ford E, Emery R, Huff D, Narayanan M, Schwartz J, Cao N, Meyer J, Rengan R, Zeng J, Sandison G, Laramore G, Mayr N.

Phys Med Biol. 2017 Jan 7;62(1):43-58. Epub 2016 Dec 14.

PMID:
27973343
13.

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.

Chao HH, Berman AT, Simone CB 2nd, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP.

J Thorac Oncol. 2017 Feb;12(2):281-292. doi: 10.1016/j.jtho.2016.10.018. Epub 2016 Nov 5.

14.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.

Maquilan G, Grover S, Xanthopoulos E, Evans TL, Aggarwal C, Langer CJ, Cohen RB, Stevenson JP, Simone CB 2nd, Rengan R.

Am J Clin Oncol. 2018 Apr;41(4):391-395. doi: 10.1097/COC.0000000000000288.

PMID:
27100960
15.

Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS; International Particle Therapy Co-operative Group Thoracic Subcommittee.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):505-16. doi: 10.1016/j.ijrobp.2016.01.036. Epub 2016 Jan 23. Review.

PMID:
27084663
16.

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Warner A, Dahele M, Hu B, Palma DA, Senan S, Oberije C, Tsujino K, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, De Ruyck K, De Dios NR, Bradley JD, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):612-20. doi: 10.1016/j.ijrobp.2015.11.030. Epub 2015 Nov 23. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):1087.

PMID:
26867890
17.

Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations.

Grover S, Chadha M, Rengan R, Williams TR, Morris ZS, Morgan DA, Tripuraneni P, Hu K, Viswanathan AN.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):957-60. doi: 10.1016/j.ijrobp.2015.08.009. Epub 2015 Aug 7.

PMID:
26581132
18.

Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data.

Chvetsov AV, Sandison GA, Schwartz JL, Rengan R.

Phys Med Biol. 2015 Nov 7;60(21):8491-503. doi: 10.1088/0031-9155/60/21/8491. Epub 2015 Oct 20.

PMID:
26485348
19.

Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions.

Berman AT, James SS, Rengan R.

Cancers (Basel). 2015 Jul 2;7(3):1178-90. doi: 10.3390/cancers7030831. Review.

20.

Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.

Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, DeRuyck K, De Dios NR, Warner A, Bradley JD, Palma DA.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
25835622
21.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

22.

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study.

Xanthopoulos EP, Handorf E, Simone CB 2nd, Grover S, Fernandes AT, Sharma S, Corradetti MN, Evans TL, Langer CJ, Mitra N, Shah A, Apisarnthanarax S, Lin LL, Rengan R.

Pract Radiat Oncol. 2015 Jul-Aug;5(4):e355-63. doi: 10.1016/j.prro.2014.11.006. Epub 2015 Jan 31.

PMID:
25649540
23.

Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O'Meara WP, Simone CB 2nd, Rengan R.

Clin Lung Cancer. 2015 May;16(3):237-44. doi: 10.1016/j.cllc.2014.12.001. Epub 2014 Dec 9.

24.

Stereotactic body radiotherapy.

Kollar L, Rengan R.

Semin Oncol. 2014 Dec;41(6):776-89. doi: 10.1053/j.seminoncol.2014.09.022. Epub 2014 Oct 7. Review.

PMID:
25499636
25.

The use of proton therapy in the treatment of lung cancers.

Simone CB 2nd, Rengan R.

Cancer J. 2014 Nov-Dec;20(6):427-32. doi: 10.1097/PPO.0000000000000080. Review.

PMID:
25415690
26.

Dynamic simulation of motion effects in IMAT lung SBRT.

Zou W, Yin L, Shen J, Corradetti MN, Kirk M, Munbodh R, Fang P, Jabbour SK, Simone CB 2nd, Yue NJ, Rengan R, Teo BK.

Radiat Oncol. 2014 Nov 1;9:225. doi: 10.1186/s13014-014-0225-3.

27.

Combination of stereotactic ablative body radiation with targeted therapies.

Zeng J, Baik C, Bhatia S, Mayr N, Rengan R.

Lancet Oncol. 2014 Sep;15(10):e426-34. doi: 10.1016/S1470-2045(14)70026-9. Review.

PMID:
25186046
28.

Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.

Lin LL, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR.

Oncol Lett. 2014 Apr;7(4):1151-1158. Epub 2014 Feb 5.

29.

International outreach: what is the responsibility of ASTRO and the major international radiation oncology societies?

Mayr NA, Hu KS, Liao Z, Viswanathan AN, Wall TJ, Amendola BE, Calaguas MJ, Palta JR, Yue NJ, Rengan R, Williams TR.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):481-4. doi: 10.1016/j.ijrobp.2013.12.052.

PMID:
24929158
30.

Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology survey.

Rengan R, Ho A, Owen JB, Komaki R, Khalid N, Wilson JF, Movsas B.

Pract Radiat Oncol. 2014 May-Jun;4(3):e167-79. doi: 10.1016/j.prro.2013.07.012. Epub 2013 Oct 8.

PMID:
24766691
31.

A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Corradetti MN, Mitra N, Bonner Millar LP, Byun J, Wan F, Apisarnthanarax S, Christodouleas J, Anderson N, Simone CB 2nd, Teo BK, Rengan R.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):307-15. doi: 10.1016/j.prro.2012.10.005. Epub 2012 Nov 29.

PMID:
24674403
32.

Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation.

Berman AT, Turowski J, Mick R, Cengel K, Farnese N, Basel-Brown L, Mesaros C, Blair I, Lawson J, Christofidou-Solomidou M, Lee J, Rengan R.

J Pulm Respir Med. 2013 Aug 30;3(4):154.

33.

Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience.

Chawla S, Wang S, Kim S, Sheriff S, Lee P, Rengan R, Lin A, Melhem E, Maudsley A, Poptani H.

J Neuroimaging. 2015 Jan-Feb;25(1):97-104. doi: 10.1111/jon.12070. Epub 2013 Nov 26.

PMID:
24279509
34.

Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.

Geiger GA, Kim MB, Xanthopoulos EP, Pryma DA, Grover S, Plastaras JP, Langer CJ, Simone CB 2nd, Rengan R.

Clin Lung Cancer. 2014 Jan;15(1):79-85. doi: 10.1016/j.cllc.2013.08.004. Epub 2013 Oct 8.

PMID:
24238934
35.

Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):690-6. doi: 10.1016/j.ijrobp.2013.07.029. Epub 2013 Sep 10. Review.

PMID:
24035329
36.

High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy.

Fang P, Tan KS, Troxel AB, Rengan R, Freedman G, Lin LL.

Breast Cancer Res Treat. 2013 Aug;141(1):125-33. doi: 10.1007/s10549-013-2663-2. Epub 2013 Aug 14.

PMID:
23942874
37.

An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.

Berman AT, Teo BK, Dolney D, Swisher-McClure S, Shahnazi K, Both S, Rengan R.

Radiat Oncol. 2013 Jun 15;8:144. doi: 10.1186/1748-717X-8-144.

38.

Stereotactic body radiation therapy for lung cancer.

Simone CB 2nd, Wildt B, Haas AR, Pope G, Rengan R, Hahn SM.

Chest. 2013 Jun;143(6):1784-1790. doi: 10.1378/chest.12-2580. Review.

PMID:
23732589
39.

Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer.

Kesarwala AH, Grover S, Rengan R.

Thorac Cancer. 2013 May;4(2):95-101. doi: 10.1111/j.1759-7714.2012.00174.x. Review.

PMID:
28920191
40.

Impact of PET staging in limited-stage small-cell lung cancer.

Xanthopoulos EP, Corradetti MN, Mitra N, Fernandes AT, Kim M, Grover S, Christodouleas JP, Evans TL, Stevenson JP, Langer CJ, Lee TT, Pryma DA, Lin LL, Simone CB 2nd, Apisarnthanarax S, Rengan R.

J Thorac Oncol. 2013 Jul;8(7):899-905. doi: 10.1097/JTO.0b013e31828e8996. Erratum in: J Thorac Oncol. 2013 Aug;8(8):1106.

41.

Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study.

Rengan R, Mitra N, Liao K, Armstrong K, Vachani A.

Lancet Oncol. 2012 Dec;13(12):1203-9. doi: 10.1016/S1470-2045(12)70466-7. Epub 2012 Nov 16.

42.

Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.

Trister AD, Pryma DA, Xanthopoulos E, Kucharczuk J, Sterman D, Rengan R.

Am J Clin Oncol. 2014 Apr;37(2):135-9. doi: 10.1097/COC.0b013e31826b9cd3.

PMID:
23111361
43.

Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals.

Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA.

AIDS. 2013 Jan 28;27(3):459-68. doi: 10.1097/QAD.0b013e32835ad56e.

44.

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, Maity A.

Mol Pharmacol. 2012 Dec;82(6):1230-40. doi: 10.1124/mol.112.080408. Epub 2012 Sep 18.

45.

Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.

Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, Divgi C, Eskola O, Sorger JM, Stabin MG, Kachur A, Hahn SM, Grönroos TJ, Forsback S, Evans SM, Koch CJ, Minn H.

Cancer Biother Radiopharm. 2012 Sep;27(7):412-9. doi: 10.1089/cbr.2011.1130. Epub 2012 Aug 16.

PMID:
22897720
46.

Central-airway necrosis after stereotactic body-radiation therapy.

Corradetti MN, Haas AR, Rengan R.

N Engl J Med. 2012 Jun 14;366(24):2327-9. doi: 10.1056/NEJMc1203770. No abstract available.

47.

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043. Epub 2012 Jun 9. Review.

48.

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

Eblan MJ, Corradetti MN, Lukens JN, Xanthopoulos E, Mitra N, Christodouleas JP, Grover S, Fernandes AT, Langer CJ, Evans TL, Stevenson J, Rengan R, Apisarnthanarax S.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):175-81. doi: 10.1016/j.ijrobp.2012.03.051. Epub 2012 Jun 1.

PMID:
22658442
49.

SU-D-211-06: The Effect of Motion in RapidArc Lung SBRT Delivery.

Zou J, Yin L, Shen J, Corradetti M, Kirk M, Rengan R, Teo BK.

Med Phys. 2012 Jun;39(6Part3):3611. doi: 10.1118/1.4734660.

PMID:
28517420
50.

SU-E-T-437: Interfractional Dosimetric Verification of Lung Patients Treated by Passive Double Scattering Proton Radiotherapy.

Tang S, Yin L, Rengan R, James P, Hahn S, Both S.

Med Phys. 2012 Jun;39(6Part16):3805. doi: 10.1118/1.4735526.

PMID:
28517213

Supplemental Content

Loading ...
Support Center